21 CFR Parts 210 & 211 — Drug CGMP for Finished Pharmaceuticals | eCFR current as of April 2026
Federal Food, Drug, and Cosmetic Act (FDCA) — Adulteration Provision:
"A drug shall be deemed to be adulterated… if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess."— FDCA §501(a)(2)(B), 21 U.S.C. §351(a)(2)(B)
This provision is the ultimate enforcement anchor for all CGMP requirements. Any drug product that deviates from CGMP is deemed adulterated under federal law — regardless of whether it actually caused patient harm.
21 CFR 210.1 — Status of Current Good Manufacturing Practice Regulations:
"(a) The regulations set forth in this part and in parts 211 through 226 and parts 600 through 680 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength, and meets the quality and purity characteristics that it purports or is represented to possess."
"(b) The failure to comply with any regulation set forth in this part and in parts 211 through 226 and parts 600 through 680 of this chapter in the manufacture, processing, packing, or holding of a drug shall render such drug to be adulterated under section 501(a)(2)(B) of the act and such drug, as well as the person who is responsible for the failure to comply, shall be subject to regulatory action."
21 CFR 210.2 — Applicability of Current Good Manufacturing Practice Regulations:
"(a) The regulations in this part and in parts 211 through 226 and parts 600 through 680 of this chapter as they may pertain to a drug; (1) apply to all persons who are manufacturers, packers, or holders of such drug marketed in the United States; (2) apply to all drugs…"
"(b) Where a person engages in only some operations subject to the regulations in this part, parts 211 through 226 and parts 600 through 680 of this chapter, such person shall comply with the regulations governing those operations."
"(c) An investigational drug for use in a Phase 1 study… is subject to legal requirements of the act relating to the safety of the drug product… [The regulations in part 211 do not apply to the manufacture of such investigational drug for human use, except where the investigational drug has been made available for a Phase 2 or Phase 3 investigation…]"
21 CFR 210.3 — Definitions:
The following definitions apply to Parts 210 through 226 and Parts 600 through 680 unless the context otherwise requires:
Batch
A specific quantity of a drug or other material that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture. *(§210.3(b)(2))*
Lot
A batch, or a specific identified portion of a batch, having uniform character and quality within specified limits; or, in the case of a drug product produced by continuous process, a specific identified amount produced in a unit of time or quantity in a manner that assures its having uniform character and quality within specified limits. *(§210.3(b)(10))*
Lot number, control number, or batch number
Any distinctive combination of letters, numbers, or symbols, or any combination of them, from which the complete history of the manufacture, processing, packing, holding, and distribution of a batch or lot of drug product or other material can be determined. *(§210.3(b)(11))*
Component
Any ingredient intended for use in the manufacture of a drug product, including those that may not appear in such drug product. *(§210.3(b)(3))*
Drug product
A finished dosage form, for example, tablet, capsule, solution, etc., that contains an active drug ingredient generally, but not necessarily, in association with inactive ingredients. The term also includes a finished dosage form that does not contain an active ingredient but is intended to be used as a placebo. *(§210.3(b)(4))*
Drug substance
An active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the body of humans or other animals. The term includes those parts of the molecule that impart the activity and may be modified to form salts, esters, or other noncovalent derivatives used as formulated intermediates. Drug substance does not include intermediates used in the synthesis of such ingredient. *(§210.3(b)(7))*
Fiber
Any particulate contaminant with a length at least three times greater than its width. *(§210.3(b)(8))*
Non-fiber releasing filter
Any filter, which after any appropriate pretreatment such as washing or flushing, will not release fibers into the component or drug product that is being filtered. All filters composed of asbestos are deemed to be fiber releasing filters. *(§210.3(b)(13))*
In-process material
Any material fabricated, compounded, blended, or derived by chemical reaction that is produced for, and used in, the preparation of the drug product. *(§210.3(b)(9))*
Strength
(1) The concentration of the drug substance (for example, weight/weight, weight/volume, or unit dose/volume basis), and/or (2) The potency, that is, the therapeutic activity of the drug product as indicated by appropriate laboratory tests or by adequately developed and controlled clinical data (expressed, for example, in terms of units by reference to a standard). *(§210.3(b)(16))*
Theoretical yield
The quantity that would be produced at any appropriate phase of manufacture, processing, or packing of a particular drug product, based upon the quantity of components to be used, in the absence of any loss or error in actual production. *(§210.3(b)(17))*
Actual yield
The quantity that is actually produced at any appropriate phase of manufacture, processing, or packing of a particular drug product. *(§210.3(b)(1))*
Percentage of theoretical yield
The ratio of the actual yield (at any appropriate phase of manufacture, processing, or packing of a particular drug product) to the theoretical yield (at the same phase), stated as a percentage. *(§210.3(b)(14))*
Active ingredient
Any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans or other animals. The term includes those components that may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect. *(§210.3(b)(7) — see also drug substance definition)*
Inactive ingredient
Any component other than an active ingredient. *(§210.3(b)(8) cross-reference)*
Acceptance criteria
Numerical limits, ranges, or other criteria for acceptance of the results of analytical procedures. While this specific term is defined in ICH Q6A and referenced throughout Part 211 (particularly §§211.160, 211.165, 211.194), Part 210.3 provides the foundational framework under which specification criteria are understood. Acceptance criteria must be established, documented, and consistently applied. *(see §211.160(b))*
Expiration date / Expiry
The date placed on the label of a drug product designating the time during which a batch of the product is expected to remain within the approved shelf life specifications if stored under defined conditions, and after which it must not be used. Part 211 §211.137 requires expiration dating for drug products. Expiration dating is a prerequisite for certain yield calculations and retention period determinations under §211.180(b). *(§211.137)*
Representative sample
A sample that consists of a number of units that are drawn based on rational criteria, such as random sampling and intended to assure that the sample accurately portrays the material being sampled. *(§210.3(b)(15))*Additional Definitions Cross-Referenced in Part 211 (not in §210.3, but important for operational context):
Quality control unit (QU) — defined by function in §211.22: "a unit that has the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products…"
Out-of-specification (OOS) result — not in Part 211 text, but addressed in FDA's 2006 OOS Guidance; test result falling outside established specifications (§211.165) or acceptance criteria triggers investigation under §211.192 / §211.194
Process validation — not defined in Part 211, but the concept underlies §§211.100, 211.110, 211.113; defined in FDA's 2011 Process Validation Guidance as collecting and evaluating data from process design through commercial production to establish scientific evidence that a process is capable of consistently delivering a quality product
21 CFR Parts 210 & 211 — Drug CGMP for Finished Pharmaceuticals | eCFR current as of April 2026
§ 211.22(a) — There shall be a quality control unit that shall have the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated. The quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company.
§ 211.22(b) — Adequate laboratory facilities for the testing and approval (or rejection) of components, drug product containers, closures, packaging materials, in-process materials, and drug products shall be available to the quality control unit.
§ 211.22(c) — The quality control unit shall have the responsibility for approving or rejecting all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product.
§ 211.22(d) — Adequate laboratory facilities for the testing and approval (or rejection) of drug products shall be available to the quality control unit. The responsibilities and procedures applicable to the quality control unit shall be in writing; such written procedures shall be followed.
Operational meaning of "written procedures shall be followed" (§211.22(d)): This clause is deceptively important. It is not enough to have written QCU SOPs — those SOPs must actually be followed in practice. FDA inspectors look for consistency between stated procedure and actual practice. Examples of noncompliance: a written procedure says QCU must review all batch records within 48 hours of completion, but batch records are routinely reviewed weeks later; a SOP mandates QCU signature on all change control approvals, but unsigned change controls are found in files. Gaps between written procedure and practice frequently become Warning Letter content, not merely 483 observations.
"The quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company."— 21 CFR §211.22(a), contract manufacturing clause
Subpart A General Scope — §211.1(a): The regulations in this part contain the minimum current good manufacturing practice for preparation of drug products (excluding positron emission tomography drugs) for administration to humans or animals. The failure to comply with any regulation in 21 CFR Part 211 causes a drug product to be adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.
§211.3 — Definitions: Key terms include: batch (a specific quantity of a drug or other material that is intended to have uniform character and quality); lot (a batch or a specific identified portion of a batch); component (any ingredient intended for use in the manufacture of a drug product); drug product container (any object that holds the drug product); quality control unit (any person or organizational element designated by the firm to be responsible for the duties relating to quality control).
Adulteration consequence of §211.1(a): The link between CGMP failure and drug adulteration is not merely administrative. Under Section 501(a)(2)(B) of the FD&C Act, a drug product manufactured, processed, packed, or held in conditions that do not conform to CGMP is deemed adulterated — regardless of whether the product itself has any measurable quality defect. This means a drug can be removed from the market, subjected to a recall, and trigger criminal liability for responsible persons, even if laboratory testing shows it meets all specifications. CGMP compliance is not optional because it produces good products; it is legally mandatory because its absence makes the product legally adulterated.
§210 vs §211 — the regulatory relationship: 21 CFR Part 210 establishes the general CGMP framework and the consequence of non-compliance (adulteration). 21 CFR Part 211 provides the detailed operational requirements. Part 210 §210.2(a) states that the failure to comply with Part 211 constitutes a failure to comply with Part 210 as well — so both parts are triggered together in any enforcement action. Understanding this dual-part structure is important when reading FDA Warning Letters, which may cite both §210 and §211 violations arising from the same observation.
21 CFR Parts 210 & 211 — Drug CGMP for Finished Pharmaceuticals | eCFR current as of April 2026
§ 211.42(a) — Any building or buildings used in the manufacture, processing, packing, or holding of a drug product shall be of suitable size, construction and location to facilitate cleaning, maintenance, and proper operations.
§ 211.42(b) — Any such building shall have adequate space for the orderly placement of equipment and materials to prevent mix-ups between different components, drug product containers, closures, labeling, in-process materials, or drug products, and to prevent contamination. The flow of components, drug product containers, closures, labeling, in-process materials, and drug products through the building or buildings shall be designed to prevent contamination.
§ 211.42(c) — Operations shall be performed within specifically defined areas of adequate size. There shall be separate or defined areas or such other control systems for the firm's operations as are necessary to prevent contamination or mix-ups during the course of the following procedures:
(1) Receipt, identification, storage, and withholding from use of components, drug product containers, closures, and labeling, pending the appropriate sampling, testing, or examination by the quality control unit before release for manufacturing or packaging;
(2) Holding of rejected components, drug product containers, closures, and labeling before disposition;
(3) Storage of released components, drug product containers, closures, and labeling;
(4) Storage of in-process materials;
(5) Manufacturing and processing operations;
(6) Packaging and labeling operations;
(7) Quarantine storage before release of drug products;
(8) Storage of drug products after release;
(9) Control and laboratory operations;
(10) Aseptic processing, which includes as appropriate:
(i) Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable;
(ii) Temperature and humidity controls;
(iii) An air supply filtered through high-efficiency particulate air filters under positive pressure, regardless of whether flow is laminar or nonlaminar;
(iv) A system for monitoring environmental conditions;
(v) A system for cleaning and disinfecting the room and equipment to produce aseptic conditions;
(vi) A system for maintaining any equipment used to control the aseptic conditions.
§ 211.42(d) — Operations relating to the manufacture, processing, and packing of penicillin shall be performed in facilities separate from those used for other drug products for human use.
"An air supply filtered through high-efficiency particulate air filters under positive pressure, regardless of whether flow is laminar or nonlaminar."— 21 CFR §211.42(c)(10)(iii), the CGMP legal basis for HEPA in aseptic areas
21 CFR Parts 210 & 211 — Drug CGMP for Finished Pharmaceuticals | eCFR current as of April 2026
§ 211.80 General requirements.
There shall be written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures; such written procedures shall be followed.§ 211.82 Receipt and storage of untested components, drug product containers, and closures.
(a) Upon receipt and before testing or examination, each lot of components, drug product containers, and closures shall be quarantined until tested or examined, as appropriate, and released for use.
(b) Components, drug product containers, and closures shall be stored under quarantine until they have been tested or examined, as appropriate, and released. Storage within the area used for components, drug product containers, and closures that have been released is permissible if the components are adequately identified as to their status.
§ 211.84 Testing and approval or rejection of components, drug product containers, and closures.
(a) Each lot of components, drug product containers, and closures shall be withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit.
(b) Representative samples of each shipment of each lot shall be collected for testing or examination. The number of containers to be sampled, and the amount of material to be taken from each container, shall be based upon appropriate criteria such as statistical criteria for component variability, confidence levels, and degree of precision desired, the past quality history of the supplier, and the quantity needed for analysis and reserve where required by §211.170.
(c) Samples shall be examined and tested as follows:
(1) At least one test shall be conducted to verify the identity of each component of a drug product. Specific identity tests, if they exist, shall be used.
(2) Each component shall be tested for conformity with all appropriate written specifications for purity, strength, and quality. In lieu of such testing by the manufacturer, a report of analysis may be accepted from the supplier of a component, provided that at least one specific identity test is conducted on such component by the manufacturer, and provided that the manufacturer establishes the reliability of the supplier's analyses through appropriate validation of the supplier's test methods at appropriate intervals.
(3) Containers and closures shall be tested for conformity with all appropriate written specifications.
(4) When appropriate, components shall be microscopically examined.
(5) Each lot of a component, drug product container, or closure that is liable to contamination with filth, insect infestation, or other extraneous adulterant shall be examined against established specifications for such contamination.
(d) Any lot of components, drug product containers, or closures that meets the appropriate written specifications of identity, strength, quality, and purity may be approved and released for use. Any lot of such material that does not meet such specifications shall be rejected.
"At least one test shall be conducted to verify the identity of each component of a drug product."— 21 CFR §211.84(c)(1), the 100% identity testing requirement
§ 211.86 Use of approved components, drug product containers, and closures.
Components, drug product containers, and closures approved for use shall be rotated so that the oldest approved stock is used first. Deviation from this requirement is permitted if such deviation is temporary and appropriate.§ 211.87 Retesting of approved components, drug product containers, and closures.
Components, drug product containers, and closures shall be retested or reexamined, as appropriate, for identity, strength, quality, and purity and approved or rejected by the quality control unit in accordance with §211.84 as necessary, e.g., after storage for long periods or after exposure to air, heat, or other conditions that might adversely affect the component, drug product container, or closure.§ 211.89 Rejected components, drug product containers, and closures.
Rejected components, drug product containers, and closures shall be identified and controlled under a quarantine system designed to prevent their use in manufacturing or processing operations for which they are unsuitable.21 CFR Parts 210 & 211 — Drug CGMP for Finished Pharmaceuticals | eCFR current as of April 2026
§ 211.122(a) There shall be written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, examination, and/or testing of labeling and packaging materials; such written procedures shall be followed. Labeling and packaging materials shall be representatively sampled, and examined or tested upon receipt and before use in packaging or labeling of a drug product.
§ 211.122(b) Any labeling or packaging materials meeting appropriate written specifications may be approved and released for use. Any labeling or packaging materials that do not meet such specifications shall be rejected to prevent their use in operations for which they are unsuitable.
§ 211.122(c) Records shall be maintained for each shipment received of each different labeling and packaging material indicating receipt, examination or testing, and whether accepted or rejected.
§ 211.122(d) Labels and other labeling materials for each different drug product, strength, dosage form, or quantity of contents shall be stored separately with suitable identification. Access to the storage area shall be limited to authorized personnel.
§ 211.122(e) Obsolete and outdated labels, labeling, and other packaging materials shall be destroyed.
§ 211.122(f) Use of gang-printed labeling for different drug products, or different strengths or net contents of the same drug product, is prohibited unless the labeling from gang-printed sheets is adequately differentiated by size, shape, or color.
§ 211.122(g) If cut labeling is used, it is subject to the following labeling identity requirements:
Separate storage areas or physical segregation of labels from labeling for different drug products, or for different strengths or net contents of the same drug product, to prevent mix-ups.
Identification of the drug product, strength, quantity of contents, and lot or control number of the drug product for which the labeling is intended on the containers of cut labeling.
Labeling defined under 21 CFR 201.1 (for context):
Container labels (primary and secondary)
Package inserts / prescribing information
Carton labeling
Patient medication guides
Any written, printed, or graphic matter accompanying a drug product
"Labeling and packaging materials shall be representatively sampled, and examined or tested upon receipt and before use in packaging or labeling of a drug product." — 21 CFR § 211.122(a)21 CFR Parts 210 & 211 — Drug CGMP for Finished Pharmaceuticals | eCFR current as of April 2026
§211.160(a) — General requirements: The establishment of any specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms required by this subpart, including any change in such specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms, shall be drafted by the appropriate organizational unit and reviewed and approved by the quality control unit. The requirements in this subpart shall be followed and shall be documented at the time of performance. Any deviation from the written specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms shall be recorded and justified.
§211.160(b) — Laboratory controls shall include:
(1) Determination of conformance to applicable written specifications for the acceptance of each lot within each shipment of components, drug product containers, closures, and labeling used in the manufacture, processing, packing, or holding of drug products.
(2) Determination of conformance to written specifications and a description of sampling and testing procedures and, where appropriate, methodological limitations for in-process materials and drug products. The sampling and testing procedures shall include the kind and number of tests; such procedures shall assure that batches of drug products meet specifications.
(3) The establishment of the accuracy, sensitivity, specificity, and reproducibility of test methods used. Such validation and documentation may be accomplished in accordance with §211.194(a)(2).
(4) The calibration of instruments, apparatus, gauges, and recording devices at suitable intervals in accordance with an established written program containing specific directions, schedules, limits for accuracy and precision, and provisions for remedial action in the event accuracy and/or precision limits are not met. Instruments, apparatus, gauges, and recording devices not meeting established specifications shall not be used.
§211.165 — Testing and release for distribution:
(a) For each batch of drug product, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Where sterility and/or pyrogen testing are conducted on specific batches of short-lived radiopharmaceuticals, such batches may be released prior to completion of sterility and/or pyrogen testing, pending the results of such testing.
(b) There shall be appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.
(c) Any sampling and testing plans shall be described in written procedures that shall include the method of sampling and the number of units per batch to be tested; such written procedure shall be followed.
(d) Acceptance criteria for the sampling and testing conducted by the quality control unit shall be adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release. The statistical quality control criteria shall include appropriate acceptance levels and/or rejection levels.
(e) The accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented. Such validation and documentation may be accomplished in accordance with §211.194(a)(2). Appropriate controls shall be used to validate results of each test method.
(f) Drug products failing to meet established standards or specifications and any other relevant quality criteria shall be rejected. Reprocessing may be performed. Prior to acceptance and use, reprocessed material must meet appropriate standards, specifications, and any other relevant criteria.
"The requirements in this subpart shall be followed and shall be documented at the time of performance. Any deviation from the written specifications… shall be recorded and justified."— 21 CFR §211.160(a)
Applying these regulatory guidelines in practice? Use our free validated calculators for risk management, sampling, and environmental monitoring.